GRI Bio, Inc. (NASDAQ:GRI) Sees Significant Drop in Short Interest

GRI Bio, Inc. (NASDAQ:GRI) saw a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 1,300 shares, a decrease of 98.2% from the May 31st total of 71,500 shares. Based on an average daily trading volume, of 76,500 shares, the short-interest ratio is currently 0.0 days. Approximately 0.5% of the shares of the stock are short sold.

GRI Bio Stock Performance

NASDAQ GRI opened at 1.96 on Friday. The business has a 50 day simple moving average of 4.43 and a two-hundred day simple moving average of 14.13. GRI Bio has a 1-year low of 1.70 and a 1-year high of 472.29.

GRI Bio (NASDAQ:GRI) last announced its earnings results on Friday, May 10th. The company reported -5.98 earnings per share (EPS) for the quarter.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.